TabletsClinical Overview
Cinnarizine and Dimenhydrinate is a dual-target vestibular formulation. Cinnarizine acts as a selective T-type calcium channel blocker, inhibiting calcium influx into vestibular sensory hair cells and dampening labyrinthine hyper-reactivity, while dimenhydrinate (diphenhydramine-theoclate salt) blocks H1 receptors in the vestibular nuclei and solitary tract, suppressing the vegetative emetic reflex. Together, they provide synergistic peripheral and central vestibular suppression. Indicated for the symptomatic treatment of various origins of vertigo in adults.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally after meals with water. Swallow tablets whole without chewing. Limit treatment duration to a maximum of 4 weeks unless directed by an ENT specialist.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Somnolence, drowsiness, dry mouth, headache, fatigue, dyspepsia. Rare/Severe: Extrapyramidal symptoms/parkinsonism with prolonged use, angle-closure glaucoma, and depression.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in severe renal impairment, severe hepatic impairment, angle-closure glaucoma, and benign prostatic hyperplasia. Avoid prolonged use (> 4 weeks) in elderly patients due to risk of drug-induced parkinsonism. Avoid driving.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Cinnarizine Tablets 25mg
Cinnarizine is a piperazine-derivative labyrinthine sedative and peripheral vasodilator. It selectively blocks voltage-gated T-type calcium channels, inhibiting trans-membrane calcium influx in vestibular sensory cells and vascular smooth muscle, improving labyrinthine microcirculation and suppressing motion-induced vestibular overstimulation. Indicated for vestibular vertigo, motion sickness prophylaxis, and peripheral vascular disorders.
Cinnarizine Tablets 75mg
Cinnarizine is a piperazine-derivative labyrinthine sedative and peripheral vasodilator. It selectively blocks voltage-gated T-type calcium channels, inhibiting trans-membrane calcium influx in vestibular sensory cells and vascular smooth muscle, improving labyrinthine microcirculation and suppressing motion-induced vestibular overstimulation. Indicated for vestibular vertigo, motion sickness prophylaxis, and peripheral vascular disorders.
Cinnarizine 20mg + Domperidone 15mg Tablet
Cinnarizine (20mg) and Domperidone (15mg) Tablets is a dual-action vestibular sedative and antiemetic combination. Cinnarizine acts as a selective T-type voltage-gated calcium channel blocker and H1-antihistamine, suppressing labyrinthine overstimulation in the inner ear. Domperidone blocks peripheral dopamine D2 receptors in the CTZ, preventing motion-induced and labyrinthine nausea. Indicated for vertigo, motion sickness, Meniere's disease, and peripheral vestibular disorders accompanied by nausea and vomiting.